A Phase 1 interventional study of Xanomeline/Trospium Chloride and Lithium in Healthy Volunteers, sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-24.
Sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the effects of lithium, valproic acid, and lamotrigine on the single-dose pharmacokinetics (PK) of KarXT and the effect of KarXT on the single-dose PK of lithium, valproic acid, and lamotrigine in healthy participants.
Karuna Therapeutics, Inc., a Bristol Myers Squibb company is the lead sponsor of 17 studies on the registry; 8 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.
First submitted after Karuna Therapeutics, Inc. became part of Bristol-Myers Squibb.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Xanomeline/Trospium Chloride · Drug: Lithium
Drug: Xanomeline/Trospium Chloride · Drug: Valproic Acid
Drug: Xanomeline/Trospium Chloride · Drug: Lithium
Drug: Xanomeline/Trospium Chloride · Drug: Valproic Acid
Drug: Xanomeline/Trospium Chloride · Drug: Lamotrigine
Drug: Xanomeline/Trospium Chloride · Drug: Lamotrigine
Drug pages: Xanomeline · Trospium chloride
Specified dose on specified days
Also known as: BMS-986510, KarXT
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Maximum observed plasma concentration (Cmax)
Time frame: Up to day 54
Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))
Time frame: Up to day 54
Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF))
Time frame: Up to day 54
Number of participants with adverse events (AEs)
Time frame: Up to 28 days post discontinuation of dosing
Number of participants with serious adverse events (SAEs)
Time frame: Up to 28 days post discontinuation of dosing
Number of participants with physical examination abnormalities
Time frame: Up to 2 days post discontinuation of dosing
Number of participants with vital sign abnormalities
Time frame: Up to 2 days post discontinuation of dosing
Number of participants with 12-lead electrocardiogram (ECG) abnormalities
Time frame: Up to 2 days post discontinuation of dosing
Number of participants with clinical laboratory abnormalities
Time frame: Up to 2 days post discontinuation of dosing
Columbia-Suicide Severity Rating Scale (C-SSRS)
Time frame: Up to 2 days post discontinuation of dosing
Number of participants with AEs of Special Interest (AESIs)
Time frame: Up to 28 days post discontinuation of dosing
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Ran from Dec 2024 to primary completion in Jan 2026, 12 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lithium · Valproic Acid · Lamotrigine
Karuna Therapeutics, Inc., a Bristol Myers Squibb company →